Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $23
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $20 to $23.
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $20 to $23.